ENTA vs KIDS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ENTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
The company exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating poor financial health and operational efficiency. While OrthoPediatrics maintains a strong gross margin (73.05%) and excellent liquidity (Current Ratio 5.55), it has failed to achieve profitability over 25 consecutive quarters. This chronic lack of earnings, combined with a bearish technical trend and significant insider selling by the CEO and COO, suggests a high-risk profile. Despite revenue growth of 17%, the inability to convert sales into net income makes the current valuation speculative.
Compare Another Pair
Related Comparisons
ENTA vs KIDS: Head-to-Head Comparison
This page compares Enanta Pharmaceuticals, Inc. (ENTA) and OrthoPediatrics Corp. (KIDS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.